In Silico Approach for Designing Potent Neuroprotective Hexapeptide
- 22 May 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 10 (6) , 3018-3030
Abstract
Alzheimer’s disease (AD) is a constantly recurring neurodegenerative disease that deteriorates over a period of time. In this pathology, connections between neurons got extremely damaged due to the deposition of senile plaques in the membrane region, which results in abnormal signal transduction process. Also, the intracellular microtubule networks got disrupted in hyperphosphorylated tau cascade of AD. Therefore, design and development of potent neuroprotective molecules are awfully needed that can instantaneously target multiple facets of AD pathogenesis to tackle this unmet medical need. Here, we have implemented a pharmacophore based in silico analysis of various neuroprotective peptides known for neurotherapeutic application in AD. Fascinatingly, we have identified an active core of these peptides and designed a library of hexapeptides. We observed that peptide “LETVNQ” (LE6) has shown significant protection ability against degeneration of neurons. Experimental evidences suggest that this peptide immensely reduced the aggregation rate of amyloid-beta (Aβ) and helped in microtubule polymerization. Intriguingly, this newly designed peptide does not have any cytotoxicity towards differentiated PC12 neurons rather it helps in neurite outgrowth. Further, LE6 helps to maintain the complex microtubule network in cells by promoting the polymerization rate of intracellular microtubule and deliberates excellent protection of neurons even after removal of nerve growth factor (NGF). Finally, we observed that this LE6 peptide has substantial stability in physiological condition, and helps to retain the healthy morphology of the primary rat cortical neurons. This excellent piece of work identifies a potent hexapeptide, which has exceptional ability to protect neurons as well as microtubule from degeneration, may come up as a potent therapeutics of AD pathogenesis in future.Keywords
Funding Information
- SERB, India (EMR/2015/002230)
This publication has 44 references indexed in Scilit:
- APOE Genotype Specific Effects on the Early Neurodegenerative Sequelae Following Chronic Repeated Mild Traumatic Brain InjuryNeuroscience, 2019
- Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy modelNeuroImage, 2019
- Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivoNature Neuroscience, 2018
- Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivoBrain, 2018
- 2018 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2018
- Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious UpdateFrontiers in Aging Neuroscience, 2017
- The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer’s DiseaseJournal of Alzheimer’s Disease, 2017
- A novel mechanism of memory loss in Alzheimer’s disease mice via the degeneration of entorhinal–CA1 synapsesMolecular Psychiatry, 2016
- The secretases: enzymes with therapeutic potential in Alzheimer diseaseNature Reviews Neurology, 2010
- The Role of Amyloid Precursor Protein Processing by BACE1, the β-Secretase, in Alzheimer Disease PathophysiologyJournal of Biological Chemistry, 2008